Effect Of Topical Aerosolized Ropivacaine(0.75%)on Response To Extubatio

Phase 1

• Conditions: Health Condition 1: O- Medical and Surgical

• Registration Number: CTRI/2020/07/026563
• Lead Sponsor: DrNaresh Yerne

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 17 October 2022

Recruitment & Eligibility

• Status: Closed to Recruitment of Participants
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

ASA PS I or II schedule, for elective surgery under general anaesthesia requiring oral endotracheal intubation with the clinically normal airway.

Exclusion Criteria

Severe cardiovascular, liver, and kidney disfunction;

Allergies to amide local anesthetics;

Patient with history of risk factor for perioperative aspiration of gastric ontents

Difficult airway or history of maxillofacial and neck surgery;

Chronic respiratory disease such as chronic obstructive pulmonary disease or asthma, recent respiratory tract infection, chronic cough, and current smoking.

Patients with reoperation because of serious adverse events such as bleeding,

Anesthesia time more than 4 h, and delayed extubation (more than 1 h without extubation)

Prolong surgery (more than 3 hr)

Transferd to the Intensive Care Unit (ICU) with the tube were eliminated.

Medications invoving angiotensin converting enzyme inhibitor

Refusal to participate in study

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
1.Hemodynamic response(Mean arterial pressure & HeartRate)toextubation; <br/ ><br>& <br/ ><br>2.Cough occurring at extubation. <br/ ><br>Timepoint: Will be assesed at extubation <br/ ><br>After 2 min <br/ ><br>After 5 min <br/ ><br>

Secondary Outcome Measures

Name	Time	Method
oneTimepoint: None